These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7545221)

  • 1. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
    Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Deo Y; Graziano R; Fisher JL; Meyer L; Mrozek-Orlowski M
    J Clin Oncol; 1995 Sep; 13(9):2281-92. PubMed ID: 7545221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu.
    Valone FH; Kaufman PA; Guyre PM; Lewis LD; Memoli V; Ernstoff MS; Wells W; Barth R; Deo Y; Fisher J
    J Hematother; 1995 Oct; 4(5):471-5. PubMed ID: 8581387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with CD64-directed immunotherapy. An overview.
    Curnow RT
    Cancer Immunol Immunother; 1997; 45(3-4):210-5. PubMed ID: 9435876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu.
    Schwaab T; Lewis LD; Cole BF; Deo Y; Fanger MW; Wallace P; Guyre PM; Kaufman PA; Heaney JA; Schned AR; Harris RD; Ernstoff MS
    J Immunother; 2001; 24(1):79-87. PubMed ID: 11211151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer.
    Repp R; van Ojik HH; Valerius T; Groenewegen G; Wieland G; Oetzel C; Stockmeyer B; Becker W; Eisenhut M; Steininger H; Deo YM; Blijham GH; Kalden JR; van de Winkel JG; Gramatzki M
    Br J Cancer; 2003 Dec; 89(12):2234-43. PubMed ID: 14676800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu.
    Pullarkat V; Deo Y; Link J; Spears L; Marty V; Curnow R; Groshen S; Gee C; Weber JS
    Cancer Immunol Immunother; 1999 Apr; 48(1):9-21. PubMed ID: 10235484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
    Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu.
    Lewis LD; Cole BF; Wallace PK; Fisher JL; Waugh M; Guyre PM; Fanger MW; Curnow RT; Kaufman PA; Ernstoff MS
    J Immunol Methods; 2001 Feb; 248(1-2):149-65. PubMed ID: 11223076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo.
    Wallace PK; Kaufman PA; Lewis LD; Keler T; Givan AL; Fisher JL; Waugh MG; Wahner AE; Guyre PM; Fanger MW; Ernstoff MS
    J Immunol Methods; 2001 Feb; 248(1-2):167-82. PubMed ID: 11223077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
    Weiner LM; Clark JI; Ring DB; Alpaugh RK
    J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.
    van Ojik HH; Repp R; Groenewegen G; Valerius T; van de Winkel JG
    Cancer Immunol Immunother; 1997; 45(3-4):207-9. PubMed ID: 9435875
    [No Abstract]   [Full Text] [Related]  

  • 16. A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies.
    Posey JA; Raspet R; Verma U; Deo YM; Keller T; Marshall JL; Hodgson J; Mazumder A; Hawkins MJ
    J Immunother; 1999 Jul; 22(4):371-9. PubMed ID: 10404439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors.
    Fury MG; Lipton A; Smith KM; Winston CB; Pfister DG
    Cancer Immunol Immunother; 2008 Feb; 57(2):155-63. PubMed ID: 17602224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    J Clin Oncol; 1996 Mar; 14(3):737-44. PubMed ID: 8622019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
    Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
    Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
    Disis ML; Schiffman K; Guthrie K; Salazar LG; Knutson KL; Goodell V; dela Rosa C; Cheever MA
    J Clin Oncol; 2004 May; 22(10):1916-25. PubMed ID: 15143085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.